Clinical trial NCT04211961 - References

Bipolar Disorder Depression — Scopolamine in Bipolar Depression

Citation(s)

•   Belmaker RH
  Bipolar disorder. N Engl J Med. 2004 Jul 29;351(5):476-86. doi: 10.1056/NEJMra035354. No abstract available.
•   Bonner TI, Buckley NJ, Young AC, Brann MR
  Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987 Jul 31;237(4814):527-32. doi: 10.1126/science.3037705. Erratum In: Science 1987 Sep 25;237(4822):237.
•   Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC
  Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006 Jul;63(7):741-7. doi: 10.1001/archpsyc.63.7.741. Erratum In: Arch Gen Psychiatry. 2006 Nov;63(11):1208.
•   Cannon DM, Klaver JK, Gandhi SK, Solorio G, Peck SA, Erickson K, Akula N, Savitz J, Eckelman WC, Furey ML, Sahakian BJ, McMahon FJ, Drevets WC
  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry. 2011 Apr;16(4):407-18. doi: 10.1038/mp.2010.24. Epub 2010 Mar 30.
•   Davis CE, Applegate WB, Gordon DJ, Curtis RC, McCormick M
  An empirical evaluation of the placebo run-in. Control Clin Trials. 1995 Feb;16(1):41-50. doi: 10.1016/0197-2456(94)00027-z.
•   Davis KL, Berger PA, Hollister LE, Defraites E
  Physostigmine in mania. Arch Gen Psychiatry. 1978 Jan;35(1):119-22. doi: 10.1001/archpsyc.1978.01770250121012.
•   Drevets WC, Furey ML
  Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010 Mar 1;67(5):432-8. doi: 10.1016/j.biopsych.2009.11.021. Epub 2010 Jan 15.
•   Dwyer JM, Lepack AE, Duman RS
  mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int J Neuropsychopharmacol. 2012 May;15(4):429-34. doi: 10.1017/S1461145711001702. Epub 2011 Nov 24.
•   Ellis JS, Zarate CA Jr, Luckenbaugh DA, Furey ML
  Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. J Affect Disord. 2014 Jun;162:39-42. doi: 10.1016/j.jad.2014.03.010. Epub 2014 Mar 26.
•   Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, Whiteford HA
  The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016 Aug;18(5):440-50. doi: 10.1111/bdi.12423.
•   Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J
  Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010 Jan 6;303(1):47-53. doi: 10.1001/jama.2009.1943.
•   Furey ML, Drevets WC, Hoffman EM, Frankel E, Speer AM, Zarate CA Jr
  Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry. 2013 Mar;70(3):280-90. doi: 10.1001/2013.jamapsychiatry.60.
•   Furey ML, Drevets WC
  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006 Oct;63(10):1121-9. doi: 10.1001/archpsyc.63.10.1121.
•   Furey ML, Nugent AC, Speer AM, Luckenbaugh DA, Hoffman EM, Frankel E, Drevets WC, Zarate CA Jr
  Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res. 2012 Mar 30;196(1):62-7. doi: 10.1016/j.psychres.2012.01.003. Epub 2012 Feb 18.
•   GERSHON S, SHAW FH
  Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet. 1961 Jun 24;1(7191):1371-4. doi: 10.1016/s0140-6736(61)92004-9. No abstract available.
•   Gillin JC, Sutton L, Ruiz C, Darko D, Golshan S, Risch SC, Janowsky D
  The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry. 1991 Jul 15;30(2):157-69. doi: 10.1016/0006-3223(91)90170-q.
•   Insel TR, Wang PS
  The STAR*D trial: revealing the need for better treatments. Psychiatr Serv. 2009 Nov;60(11):1466-7. doi: 10.1176/ps.2009.60.11.1466.
•   Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ
  Cholinergic reversal of manic symptoms. Lancet. 1972 Jun 3;1(7762):1236-7. doi: 10.1016/s0140-6736(72)90956-7. No abstract available.
•   Janowsky DS
  Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients. Curr Psychiatry Rep. 2011 Dec;13(6):443-5. doi: 10.1007/s11920-011-0239-6.
•   Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S
  Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 Nov;73(11):1428-33. doi: 10.4088/JCP.12m07706. Epub 2012 Oct 16.
•   Kroon JS, Wohlfarth TD, Dieleman J, Sutterland AL, Storosum JG, Denys D, de Haan L, Sturkenboom MC
  Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord. 2013 May;15(3):306-13. doi: 10.1111/bdi.12058. Epub 2013 Mar 27.
•   Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thompson K, Mellow AM, Cohen RM, Murphy DL
  The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry. 1988 Oct;45(10):906-12. doi: 10.1001/archpsyc.1988.01800340028004.
•   Poland RE, Tondo L, Rubin RT, Trelease RB, Lesser IM
  Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol abnormalities in depression. Biol Psychiatry. 1989 Feb 15;25(4):403-12. doi: 10.1016/0006-3223(89)90193-5.
•   Popa D, El Yacoubi M, Vaugeois JM, Hamon M, Adrien J
  Homeostatic regulation of sleep in a genetic model of depression in the mouse: effects of muscarinic and 5-HT1A receptor activation. Neuropsychopharmacology. 2006 Aug;31(8):1637-46. doi: 10.1038/sj.npp.1300948. Epub 2005 Nov 9.
•   Porter AC, Bymaster FP, DeLapp NW, Yamada M, Wess J, Hamilton SE, Nathanson NM, Felder CC
  M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res. 2002 Jul 19;944(1-2):82-9. doi: 10.1016/s0006-8993(02)02721-x.
•   ROWNTREE DW, NEVIN S, WILSON A
  The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry. 1950 Feb;13(1):47-62. doi: 10.1136/jnnp.13.1.47. No abstract available.
•   Yildiz A, Vieta E, Leucht S, Baldessarini RJ
  Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011 Jan;36(2):375-89. doi: 10.1038/npp.2010.192. Epub 2010 Oct 27.

A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode

Details for clinical trial NCT04211961